Yoshimasa Saito

List of Publications by Year
in descending order

46	3,550	236925 25	233421 45
papers	citations	h-index	g-index

47	47	47	5575
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions. Cancer Cell, 2022, 40, 226-230.	16.8	10
2	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell, 2021, 28, 816-832.	11.1	133
3	The Effects of Continuous and Withdrawal Voluntary Wheel Running Exercise on the Expression of Senescence-Related Genes in the Visceral Adipose Tissue of Young Mice. International Journal of Molecular Sciences, 2021, 22, 264.	4.1	6
4	Establishment and Long-Term Culture of Organoids Derived from Human Biliary Tract Carcinoma. STAR Protocols, 2020, 1, 100009.	1.2	6
5	An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell, 2020, 183, 1420-1435.e21.	28.9	111
6	Establishment of an organoid bank of biliary tract and pancreatic cancers and its application for personalized therapy and future treatment. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1906-1910.	2.8	13
7	Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. IScience, 2019, 21, 624-637.	4.1	15
8	Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. Cancers, 2019, 11, 116.	3.7	27
9	Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Reports, 2019, 27, 1265-1276.e4.	6.4	137
10	Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through AKT Phosphorylation and Reactive Oxygen Species. Cancers, 2019, 11, 1993.	3.7	10
11	Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes. ELife, 2019, 8, .	6.0	46
12	Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. Scientific Reports, 2018, 8, 2821.	3.3	30
13	Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan. Therapeutic Innovation and Regulatory Science, 2018, 52, 442-448.	1.6	5
14	Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy. Therapeutic Innovation and Regulatory Science, 2018, 52, 718-723.	1.6	12
15	Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging. Npj Aging and Mechanisms of Disease, 2018, 4, 1.	4.5	26
16	Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. Journal of Clinical Biochemistry and Nutrition, 2018, 63, 123-128.	1.4	2
17	Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells. BMC Cancer, 2018, 18, 680.	2.6	12
18	Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget, 2018, 9, 9925-9939.	1.8	98

#	Article	IF	Citations
19	Cluster microRNAs miRâ€194 and miRâ€215 suppress the tumorigenicity of intestinal tumor organoids. Cancer Science, 2017, 108, 678-684.	3.9	17
20	Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. International Journal of Molecular Sciences, 2017, 18, 1111.	4.1	39
21	Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis. BMC Gastroenterology, 2017, 17, 136.	2.0	46
22	Inhibition of DNA Methylation Suppresses Intestinal Tumor Organoids by Inducing an Anti-Viral Response. Scientific Reports, 2016, 6, 25311.	3.3	23
23	microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line. BMC Cancer, 2016, 16, 732.	2.6	4
24	microRNA-34a as a Therapeutic Agent against Human Cancer. Journal of Clinical Medicine, 2015, 4, 1951-1959.	2.4	69
25	First-line eradication forHelicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced byCYP2C19genotype. World Journal of Gastroenterology, 2015, 21, 13548.	3.3	27
26	Prominent Steatosis with Hypermetabolism of the Cell Line Permissive for Years of Infection with Hepatitis C Virus. PLoS ONE, 2014, 9, e94460.	2.5	32
27	Silencing of microRNAâ€122 is an early event during hepatocarcinogenesis from nonâ€alcoholic steatohepatitis. Cancer Science, 2014, 105, 1254-1260.	3.9	71
28	Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review. Clinical Reviews in Allergy and Immunology, 2014, 47, 128-135.	6.5	71
29	Alterations of epigenetics and micro<scp>RNA</scp> in hepatocellular carcinoma. Hepatology Research, 2014, 44, 31-42.	3.4	42
30	Derangement of ghrelin secretion after longâ€term highâ€fat diet feeding in rats. Hepatology Research, 2013, 43, 1105-1114.	3.4	12
31	Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies. Antimicrobial Agents and Chemotherapy, 2012, 56, 1643-1645.	3.2	50
32	Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs. Biochemical and Biophysical Research Communications, 2012, 426, 33-37.	2.1	18
33	Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication. PLoS ONE, 2012, 7, e47396.	2.5	101
34	Role of CTCF in the regulation of microRNA expression. Frontiers in Genetics, 2012, 3, 186.	2.3	29
35	Dysfunctional Gastric Emptying With Down-regulation of Muscle-Specific MicroRNAs in Helicobacter pylori-Infected Mice. Gastroenterology, 2011, 140, 189-198.	1.3	66
36	MicroRNAs in Hepatobiliary and Pancreatic Cancers. Frontiers in Genetics, 2011, 2, 66.	2.3	36

#	Article	IF	Citations
37	Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochemical and Biophysical Research Communications, 2009, 379, 726-731.	2.1	214
38	Cancer Epigenetics: Modifications, Screening, and Therapy. Annual Review of Medicine, 2008, 59, 267-280.	12.2	241
39	A strategy aimed at low risk ESD and Four days clinical pathway for superficial gastric neoplasias. Progress of Digestive Endoscopy, 2008, 73, 58-61.	0.0	0
40	Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 2006, 9, 435-443.	16.8	1,253
41	Epigenetic Activation of Tumor Suppressor MicroRNAs in Human Cancer Cells. Cell Cycle, 2006, 5, 2220-2222.	2.6	266
42	Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. Hepato-Gastroenterology, 2005, 52, 1491-6.	0.5	5
43	Interferonâ€associated retinopathy in a uniform regimen of natural interferonâ€Î± therapy for chronic hepatitis C. Liver, 2001, 21, 192-197.	0.1	39
44	Interferon regulatory factor 1 promoter polymorphism and response to type 1 interferon. Journal of Cellular Biochemistry, 2001, 81, 191-200.	2.6	19
45	Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. Journal of Cellular Physiology, 2001, 187, 392-401.	4.1	39
46	Reduction of câ€myc expression by an antisense approach under Cre/loxp switching induces apoptosis in human liver cancer cells. Journal of Cellular Physiology, 2001, 188, 56-66.	4.1	21